+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Zonegran"

Refractory Epilepsy Treatment Market - A Global and Regional Analysis: Focus on Treatment Type, Patient Type, Seizure Type, Distribution Channel, and Regional Analysis - Analysis and Forecast, 2025-2035 - Product Thumbnail Image

Refractory Epilepsy Treatment Market - A Global and Regional Analysis: Focus on Treatment Type, Patient Type, Seizure Type, Distribution Channel, and Regional Analysis - Analysis and Forecast, 2025-2035

  • Report
  • June 2025
  • 147 Pages
  • Global
From
Epilepsy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Thumbnail Image

Epilepsy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • May 2024
  • 140 Pages
  • Global
From
  • 2 Results (Page 1 of 1)
Loading Indicator

Zonegran is a brand of antiepileptic drug (AED) used to treat seizures in adults with epilepsy. It is a sulfamate-substituted monosaccharide that works by decreasing the release of glutamate, an excitatory neurotransmitter, in the brain. Zonegran is part of the Central Nervous System (CNS) drug market, which includes drugs used to treat neurological disorders such as epilepsy, Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Zonegran is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2000. It is used as an adjunctive therapy for partial seizures in adults with epilepsy, and is also used to treat bipolar disorder. It is available in both immediate-release and extended-release formulations. The CNS drug market is highly competitive, with many large pharmaceutical companies competing for market share. Some of the major players in the Zonegran market include Eisai, Inc., GlaxoSmithKline, Pfizer, Inc., and Teva Pharmaceuticals. Show Less Read more